Biogened (WAR:BGD) Interest Expense: zł-2.1 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:BGD Biogened SA WAR:BGD
69 GF Score
Price zł19.60
GF Value zł24.02
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biogened Interest Expense?

Biogened WAR:BGD -5.77% 69 Interest Expense is zł-2.1 Mil as of Mar. 2026. GuruFocus rates WAR:BGD with a GF Score™ of 69/100 and a GF Value™ of zł24.02 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biogened's interest expense for the three months ended in Mar. 2026 was zł -0.4 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was zł-2.1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biogened's Operating Income for the three months ended in Mar. 2026 was zł 4.7 Mil. Biogened's Interest Expense for the three months ended in Mar. 2026 was zł -0.4 Mil. Biogened's Interest Coverage for the quarter that ended in Mar. 2026 was 10.50. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biogened  (WAR:BGD) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biogened's Interest Expense for the three months ended in Mar. 2026 was zł-0.4 Mil. Its Operating Income for the three months ended in Mar. 2026 was zł4.7 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was zł16.6 Mil.

Biogened's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*4.715/-0.449
=10.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Biogened Interest Expense Historical Data

* Premium members only.

The historical data trend for Biogened's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogened Interest Expense Chart

Biogened Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.60 -1.70 -2.16 -2.37 -2.21

Biogened Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.58 -0.64 -0.52 -0.48 -0.45
WAR:BGD
69GF Score
Biogened SA WAR:BGD
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogened Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-2.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of zł-2.1 Mil mean?
Biogened (WAR:BGD) has a Interest Expense of zł-2.1 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Biogened and its competitors.
Is Biogened's Interest Expense too high?
Biogened's current Interest Expense is zł-2.1 Mil. Overall, Biogened has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's Interest Expense compare to ZTS and UTHR?
Biogened's Interest Expense of zł-2.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Biogened and its competitors. Biogened's current Interest Expense is zł-2.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł24.02, compared to a current price of zł19.60 — trading 18.4% below its estimated fair value. The current Interest Expense is zł-2.1 Mil. Biogened's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Biogened (WAR:BGD), the current Interest Expense is zł-2.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogened (WAR:BGD) Overvalued in 2026?

Based on GuruFocus' analysis, Biogened stock appears to be undervalued. The current stock price of zł19.60 is trading 18.4% below its estimated GF Value™ of zł24.02. GuruFocus considers Biogened to be Modestly Undervalued.

Key valuation signals for WAR:BGD:

  • Interest Expense: zł-2.1 Mil
  • GF Value™: zł24.02 vs. price of zł19.60 (18.4% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogened Business Description

Address Ulica Pojezierska 99, Lodz, POL, 91-342
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
69GF Score

Get the complete analysis for WAR:BGD

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł19.60
Price
zł24.02
GF Value